Our organization was approached by Esther Landhuis, an independent journalist, to write an article discussing the Tolerance Induction Program in the Summer of 2020. The article published on her behalf is unfortunately inaccurate in many dates, locations, and terms.
In the past, our organization has gladly allowed reporters to write about the processes and programs of the institute. Esther Landhuis visited our organization for a short half-day tour of only a few of our five facilities. The journalist claimed to be an immunologist and did not pursue questions focused on the complex immunological model of the Tolerance Induction Program. The article published on her behalf is unfortunately inaccurate in many dates, locations, and terms. Such a publication does not reflect the diligent, detailed work which is the Tolerance Induction Program.
Interestingly, the article critiques the institute and the Tolerance Induction Program from research universities and private allergists who state SoCal Food Allergy is secret about its process. The Tolerance Induction Program involves trillions of data points, years of specific personnel training, and complex proprietary software support systems. This type of system cannot be readily shared with classically trained physicians. This would be similar to allowing a surgeon access to a surgical robot without any training on the device. Nonetheless, the criticisms are not new. These entities have criticized the novel approach of TIP for years. These entities have not successfully treated food anaphylaxis patients to date. These entities, in addition, cannot demonstrate failures of the Tolerance Induction Program. The journalist spent over six months investigating TIP™ looking for failures. The few stories represented do not reflect any new information. We maintain a well over 99% success rate in achieving remission.
What is missing from this journalist’s investigation is:
– SoCal Food Allergy and TPIRC are being funded and grown by one Founder’s monetary support
– Artificial Intelligence and Machine Learning Development model designs
– Multitude of regulatory agencies who govern TIP
– Extremely high safety rates
– Ability to maintain weekly dosing of sustained unresponsiveness
– Manufacturing facility production of dose-specific proteins
– 24/7 on-call support center
– Hundreds of biomarkers tested in our lab are unavailable elsewhere
– Treatment of all patients, all complexities from around the US and the world.
Being on the cutting edge of medicine requires focus, dedication, and gravitas to see every patient to the finish line. As long as our patients don’t give up, we do not give up. The most significant absence in the article is the thousands of successful patient stories, which reflect our ultimate promise: remission from food anaphylaxis.
If you would like to read the article we are referencing, here is the link.
Inderpal Randhawa, MD
Founder, TPIRC + SoCal Food Allergy